Evaluating FLT PET imaging for mesothelioma treatment response
Evaluation of the Response to Chemo-Therapy by FLT PET in Mesothelioma
This study is testing if a special type of imaging can help doctors see how well chemotherapy is working for people with pleural mesothelioma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ankara University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Ankara) |
| Trial ID | NCT06410625 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of FLT PET imaging in assessing the treatment response of patients with pleural mesothelioma who are undergoing platinum-based chemotherapy. The research aims to improve early diagnosis and management of this aggressive cancer, which is often diagnosed at an advanced stage. By utilizing advanced imaging techniques, the study seeks to provide insights into how well patients are responding to their chemotherapy regimen. The ultimate goal is to enhance treatment outcomes and survival rates for affected individuals.
Who should consider this trial
Good fit: Ideal candidates for this study are adults with a confirmed diagnosis of pleural mesothelioma who are scheduled to receive platinum-based chemotherapy.
Not a fit: Patients under 18 years old or those planned for immunotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring of treatment responses in mesothelioma patients, potentially enhancing survival rates.
How similar studies have performed: While the use of imaging techniques in cancer treatment response evaluation is established, the specific application of FLT PET in mesothelioma is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having a histopathologically confirmed diagnosis of Pleural Mesolthelioma * Patients planned for platinum-based chemotherapy * Patients who gave informed consent form to participate in the study Exclusion Criteria: * Being under 18 years old * Patients planned for immunotherapy * Patients who did not provide informed consent form to participate in the study
Where this trial is running
Ankara
- Ankara University Medical School — Ankara, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Cigdem Soydal, Asc Prof
- Email: csoydal@yahoo.com
- Phone: +903125956732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.